• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by SQZ Biotechnologies Company (Amendment)

    2/13/24 5:13:06 PM ET
    $SQZ
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SQZ alert in real time by email
    SC 13G/A 1 tm245791d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549 

     

     

    SCHEDULE 13G

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED

    PURSUANT TO § 240.13d-1(b), (c) AND (d) AND

    AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2

    (Amendment No. 3)*

     

     

    SQZ Biotechnologies Company

    (Name of Issuer)

     

    Common Stock, Par Value $0.01 per Share

    (Title of Class of Securities)

     

    78472W104

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    x Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosure provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”), or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 78472W104 Page 2 of 6

     

    1.

    Name of reporting persons

     

    American International Group, Inc.

    2.

    Check the appropriate box if a member of a group

     

    (a)  ¨         (b)  ¨

    3. SEC use only
    4.

    Citizenship or place of organization

     

    Incorporated under the laws of the State of Delaware

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with

    5.

    Sole voting power

     

    0

    6.

    Shared voting power

     

    2,517,173

    7.

    Sole dispositive power

     

    0

    8.

    Shared dispositive power

     

    2,517,173

    9.

    Aggregate amount beneficially owned by each reporting person

     

    2,517,173

    10. Check box if the aggregate amount in Row (9) excludes certain shares  ¨
    11.

    Percent of class represented by amount in Row (9)

     

    8.5%

    12.

    Type of reporting person

     

    HC

     

     

     

     

      Page 3 of 6

     

    ITEM 1 (a). NAME OF ISSUER:

     

    SQZ Biotechnologies Company

     

    ITEM 1 (b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:

     

    200 Arsenal Yards Blvd, Suite 210, Watertown, MA 02472

     

    ITEM 2 (a). NAME OF PERSON(S) FILING:

     

    American International Group, Inc.

     

    ITEM 2 (b). ADDRESS OF PRINCIPAL BUSINESS OFFICE(S):

     

    American International Group, Inc.

     

    1271 Avenue of the Americas, 11th Floor,

     

    New York, NY 10020

     

    ITEM 2 (c). CITIZENSHIP:

     

    Delaware

     

    ITEM 2 (d). TITLE OF CLASS OF SECURITIES:

     

    Common Stock

     

    ITEM 2 (e). CUSIP NUMBER:

     

    78472W104

     

    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b), OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

    This Item 3 is not applicable.

     

     

     

     

      Page 4 of 6

     

    ITEM 4. OWNERSHIP.

     

    (a) Reporting Person may be deemed to beneficially own 2,517,173 shares of common stock owned by its indirect subsidiaries in the amount of: (i) 1,265,702 shares are owned directly by Corebridge DECO II, LLC; (ii) 533,495 shares are owned directly by American Home Assurance Company; (iii) 343,442 shares are owned directly by Lexington Insurance Company; and (iv) 374,534 shares are owned directly by National Union Fire Insurance Company of Pittsburgh, Pa.

     

    (b) The information requested hereunder is set forth under Items 5 through 9 of the cover pages to this Schedule 13G.

     

    (c) The information requested hereunder is set forth under Item 11 of the cover pages to this Schedule 13G.

     

    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF CLASS.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨

     

    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

     

    Clients of the reporting persons may have the right to receive or the power to direct the receipt of dividends from, and the proceeds from the sale of, such securities which are the subject of this filing.

     

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

     

    See Exhibit 1 attached hereto for the information requested hereunder with respect to the relevant subsidiaries of American International Group, Inc.

     

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

     

    Not applicable.

     

    ITEM 9. NOTICE OF DISSOLUTION OF GROUP.

     

    Not applicable.

     

    ITEM 10. CERTIFICATION.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

      Page 5 of 6

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 13, 2024

     

      AMERICAN INTERNATIONAL GROUP, INC.
         
      By: /s/ Sabra R. Purtill
      Name:   Sabra R. Purtill
      Title: Chief Financial Officer

     

     

     

     

      Page 6 of 6

     

    EXHIBIT INDEX

     

    Exhibit 99.1 Identification of the Subsidiaries Which Acquired the Security Being Reported on by the Parent Holding Company

     

     

     

    Get the next $SQZ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SQZ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SQZ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SQZ Biotechnologies to Consolidate Shares with 1-for-10 Reverse Stock Split

      Company Received Notice Regarding NYSE Continued Listing Standards Section 802.01B SQZ Biotechnologies Company (NYSE:SQZ) (the "Company" or "SQZ"), focused on unlocking the full potential of cell therapies, today announced that its Board of Directors (the "Board") has approved a 1-for-10 reverse stock split ("reverse split") of its common stock, par value $0.001 per share ("Common Stock"), that is expected to become effective on Thursday, July 6, 2023 at 5:00 p.m. Eastern Time (the "Effective Date"). The Company's common stock is expected to begin trading on a split-adjusted basis on the New York Stock Exchange ("NYSE") on July 7, 2023, under the existing symbol "SQZ" and new CUSIP number

      6/15/23 4:30:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SQZ Biotechnologies Reports First Quarter 2023 Financial Results and Recent Portfolio Updates

      Phase 1 SQZ-AAC-HPV-101 Clinical Trial Resumed Following the Observation of a Confirmed Complete Response in the First Patient in the Lowest-Dose Cohort; Anticipate Data for the Highest-Dose Cohort in the Fourth Quarter of 2023 SQZ® eAPC Phase 1/2 Trial Enrollment on Track; Anticipate Data for the Highest-Dose Monotherapy Cohort in Mid-2023 SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies, today reported first quarter 2023 financial results and recent portfolio updates. "The confirmed complete response in our first patient in the AAC trial has brought enthusiasm to our trial sites, and we are encouraged by the positive momentum for e

      5/10/23 4:45:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SQZ Biotechnologies Announces Confirmed Complete Response in HPV16+ Solid Tumor Patient in the Lowest-Dose Cohort of the SQZ-AAC-HPV-101 Clinical Trial

      A confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial Following review and recommendation by the Study Safety Committee, the Company is advancing SQZ-AAC-HPV-101 trial to the highest-dose cohort Strong enrollment rates; Anticipate initial clinical data from the highest-dose cohort in the fourth quarter of 2023 SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies, today announced that, according to RECIST 1.1 criteria, a confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial. The co

      3/22/23 4:50:00 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care

    $SQZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Vink Patrick V.J.J.

      4 - SQZ Biotechnologies Co (0001604477) (Issuer)

      6/15/23 4:48:26 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Srivastava Sapna

      4 - SQZ Biotechnologies Co (0001604477) (Issuer)

      6/15/23 4:47:28 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 4 filed by Schulman Amy W

      4 - SQZ Biotechnologies Co (0001604477) (Issuer)

      6/15/23 4:46:40 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care

    $SQZ
    SEC Filings

    See more
    • SEC Form DEFM14A filed by SQZ Biotechnologies Company

      DEFM14A - SQZ Biotechnologies Co (0001604477) (Filer)

      1/23/24 4:31:01 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form PREM14A filed by SQZ Biotechnologies Company

      PREM14A - SQZ Biotechnologies Co (0001604477) (Filer)

      1/12/24 8:57:36 AM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 15-12G filed by SQZ Biotechnologies Company

      15-12G - SQZ Biotechnologies Co (0001604477) (Filer)

      1/4/24 4:15:33 PM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care

    $SQZ
    Financials

    Live finance-specific insights

    See more
    • SQZ Biotechnologies Announces Lead Cell Therapy Candidate Induced Radiographic, Symptomatic and Immune Response as Monotherapy in Post-Checkpoint HPV+ Solid Tumor Patient

      Patient's Clinical, Radiographic and Histologic Results Support Potential Impact of SQZ Investigational Therapeutic  Patient Demonstrated Symptomatic Improvement Radiographic Response Observed in Target Lesion Tumor Conversion from Desert to Inflamed Phenotype with 8-Fold Increase in CD8 T Cell Tumor Infiltration and 50-Fold Increase in Tumor PD-L1 Expression Interim Results from Ongoing Phase 1/2 Trial Showed Favorable Safety Data and Investigational Therapy was Generally Well Tolerated  Company to Host Conference Call Today at 8:00 a.m. ET SQZ Biotechnologies Company (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today presented

      12/9/21 6:10:00 AM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care
    • SQZ Biotechnologies Lead Cell Therapy Candidate Generated Monotherapy Clinical Response Correlated with Substantial CD8 T Cell Tumor Infiltration in HPV+ Solid Tumor at Highest Dose

      Interim SQZ-PBMC-HPV Results from Ongoing Phase 1/2 Trial Showed Favorable Safety Data and that Therapy was Generally Well Tolerated Oral Presentation at ESMO Immuno-Oncology Congress on December 9 to Focus on Highest-Dose Monotherapy Cohort of SQZ™ APC Candidate Company to Host Conference Call on December 9 at 8:00 a.m. ET SQZ Biotechnologies Company (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced interim results from the highest-dose monotherapy cohort of its ongoing Phase 1/2 clinical trial of SQZ-PBMC-HPV, an investigational cell therapy being evaluated in certain patients with advanced or metastatic Human Papillomavirus

      12/2/21 6:15:00 AM ET
      $SQZ
      Medicinal Chemicals and Botanical Products
      Health Care